Episodes Of Atrial Arrhythmias Research Articles

Arrhythmia Detection in Atrioventricular, Single-Lead, Floating Atrial Dipole ICD Systems Compared with Conventional Single- and Dual-Chamber Defibrillators.

An atrioventricular defibrillator system with a floating atrial dipole (VDD ICD) can provide atrial sensing by a single lead. Our aim was to compare the arrhythmia detection efficacy of VDD ICDs with conventional single- (VVI) and dual-chamber (DDD) defibrillators. Data from consecutive patients undergoing ICD implantation were retrospectively analyzed. The primary endpoint was the incidence of device-detected, new-onset atrial arrhythmias, while secondary endpoints were sensing parameters, complication rates, incidence of appropriate/inappropriate ICD therapy, arrhythmic/heart failure-related hospitalizations, and all-cause mortality. A total of 256 patients (mean age 64 ± 12 years, male 75%, primary prophylaxis 28%, mean follow-up 3.7 ± 2.4 years) were included (VVI: 93, VDD: 94, DDD: 69). Atrial arrhythmia episodes were detected more frequently by VDD systems compared to VVI ICDs (aHR 7.087; 95% CI 2.371-21.183; p < 0.001), and at a rate similar to that of DDD ICDs (aHR 1.781; 95% CI 0.737-4.301; p = 0.200). The rate of inappropriate shocks was not different among the three ICD systems. VDD devices revealed an advantage in atrial arrhythmia detection compared to VVI ICDs and were non-inferior to DDD systems. Their main indication may be closer monitoring in high-risk patients with atrial arrhythmias to help therapy optimization and not the improvement of tachycardia discrimination.

Patient-triggered Events Poorly Predict the Presence of Atrial Tachyarrhythmia on Ambulatory Electrocardiogram Monitors in Patients With Heart Failure.

Ambulatory electrocardiogram (AECG) monitoring is an attractive method for objectively identifying atrial fibrillation (AF) symptoms by documenting simultaneous arrhythmia with symptomatic episodes. However, no study yet has evaluated this simultaneous symptom-rhythm correlation in patients with heart failure (HF). We aimed to measure the correlation between symptoms and atrial arrhythmia (ATAF) episodes among patients with HF and known AF using prolonged AECG monitoring. We analyzed ATAF events and patient-triggered symptomatic events (PTSEs) on AECG monitors in adults with a history of AF and HF. Among 959 monitors, we identified a total of 26,634 events, including 15,787 ATAF events and 4950 PTSE. The mean age was 70 years, 48% were female, and 91% were Caucasian. Among 4950 PTSEs, only 1116 demonstrated ATAF (23%). PTSE showed a low correlation with ATAF, with a moderate inverse tetrachoric correlation of -0.62 (bootstrapped 95% confidence interval: -0.61 to -0.63). The mean heart rate (HR) of symptomatic ATAF events was 115 bpm (SD: 33), compared with asymptomatic ATAF (107 bpm, SD: 33, P < 0.001). The mean HR of all symptomatic events was 92 bpm (SD: 28) and of asymptomatic events was 99 bpm (SD: 30), P < 0.001. Our study found that symptomatic events on AECG monitors poorly predict ATAF episodes, ATAF episodes are rarely noted as symptomatic, and poor HR control fails to fully explain AF symptoms in patients with known AF and HF. Our study encourages further research into other symptom assessments, such as patient-reported outcomes and a more comprehensive approach to AF treatment in HF rather than primarily symptom based.

Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial.

The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure. AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design). Patients were randomized in a 1:1:1 ratio after PFO closure to receive flecainide (150 mg once daily in a sustained-release dose) for 3 months, flecainide (150 mg once daily in a sustained-release dose) for 6 months, or no additional treatment (standard of care) for 6 months. The primary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor. The secondary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded with insertable cardiac monitor during the 3- to 6-month period after PFO closure. A total of 186 patients were included (mean age, 54 years; 68.8% men) and AA (≥30 seconds) occurred in 53 patients (28.5%) during the 6-month follow-up; 86.8% of these AA events occurred in the first month after PFO closure. The primary outcome occurred in 33 of 123 (26.8%) and 16 of 63 (25.4%) patients receiving flecainide for at least 3 months or standard of care, respectively (risk difference, 1.4% [95% CI, -12.9% to 13.8%]; NS). The secondary end point occurred in 3 of 60 (5.0%), 4 of 63 (6.3%), and 5 of 63 (7.9%) patients receiving flecainide for 6 months, for 3 months, or standard of care, respectively (risk difference, -2.9% [95% CI, -12.7% to 6.9%], and risk difference, -1.6% [95% CI, -11.8% to 8.6%], respectively). In the first 6 months after successful PFO closure, AA (≥30 seconds) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05213104.

No improvement in atrial arrhythmia rates in patients on baroreflex activation therapy

Abstract Background Atrial arrhythmias encompass a wide range of abnormal cardiac rhythms including atrial fibrillation, atrial flutter, and atrial tachycardia. Patients with heart failure with reduced ejection fraction (HFrEF) have increased risk of atrial arrhythmias, ultimately leading to increased morbidity. Baroreflex Activation Therapy (BAT) employs an implantable device to increase parasympathetic nervous system activity by stimulating the carotid baroreceptors thereby reducing afterload and heart failure symptoms. In our prior study, BAT therapy has been shown to reduce hospitalization rates in patients with HFrEF. However, the effects of BAT on atrial arrhythmia has never been studied. Objective In this study, we analyzed the effects of BAT on atrial arrhythmia rates in patients with HFrEF. Methods Patients with HFrEF with BAT therapy for at least 12-months at a hospital were retrospectively studied. Inclusion criteria includes implantable cardioverter-defibrillator (ICD) placement of at least 12-months pre- and post-BAT therapy. Additionally, patients diagnosed with atrial arrhythmias prior to the study timeline were excluded. Atrial arrhythmia rates 6 and 12-months pre-BAT therapy and 6 and 12-months post-BAT therapy were compared. Atrial arrhythmia episodes were recorded through ICD interrogation every 1-3 months in the clinic. Of the 31 identified patients on BAT therapy, 11 patients fit the inclusion criteria. For the 11 patients in the study, 3 identified as female and 8 identified as male, 6 identified as white, 4 identified as Hispanic, and 1 identified as African-American with a mean age of 59.8 ± 17.4 years. The average left ventricular ejection fraction pre-BAT therapy was 23.8 ± 10.8%. Results The mean average atrial arrhythmia rates for 6-month pre-BAT therapy and 6-month post-BAT therapy were 0.12/month ± 0.40 and 1.32/month ± 2.76 respectively (p=0.18), suggesting no differences in atrial arrhythmia rates at 6-months with BAT therapy. The mean average atrial arrhythmia rates for 12-month pre-BAT therapy and 12-month post-BAT therapy were 0.11/month ± 0.35 and 2.40/month ± 5.84 respectively (p=0.22), suggesting no differences in atrial arrhythmia rates at 12-months with BAT therapy. Conclusion Although BAT therapy has been shown to decrease hospitalization rates, BAT therapy is not associated with decreased atrial arrhythmia rates at 6 months and 12 months.

Pulmonary vein isolation combined with a new protocol of linear ablation to treat persistent atrial fibrillation: a prospective cohort with 1 year follow-up

Abstract Background The clinical value of ablation strategies beyond pulmonary vein isolation (PVI) in patients with persistent atrial fibrillation (perFA) is not clearly established and the optimal strategy to cure perFA remains a challenge due to the high recurrence rate after PVI alone (up to 50% of patients during 1-year follow-up). Purpose To determine the additional therapeutic value of a new design of linear ablation in the left atrium (LA) added to PVI in patients with perFA. Methods In this prospective study consecutive patients with perFA were included and underwent PVI combined with a predefined homogeneous protocol of linear ablation in the LA: anterolateral line from the mitral annulus to the left superior pulmonary vein around the left atrial appendage, anteroseptal line and posterior wall isolation. Patients were followed during 12 months after ablation with daily 30 s single-lead ECG obtained with mobile applications. The main endpoint was the incidence of recurrences, defined as any documented, sustained (&amp;gt;30 s) episodes of atrial arrhythmia that occurred after a 3 months blanking period. Antiarrhythmic drugs were avoided after the blanking period. Results 59 patients were included (61 [IQR 53-69] years old, 76% male sex). Acutely successful PVI was achieved in all patients and the linear ablation protocol was performed in 52 (89,7%) patients. The linea ablation protocol was not completed in 6 patients due to the following reasons: repetitive AF triggering from the same PV in 2 patients, induction and successful focal ablation of left atrial flutter in 1 patient, respiratory failure in 1 patient with severe obstructive lung disease and excessively prolonged procedure time in 2 patients. 58 patients completed the 12 months follow-up period and 1 patient was lost due to end-stage heart failure. The survival free of atrial arrhythmia recurrences was 69.1% [95%CI 55.1-79.5] (Figure). No patient had recurrences of perAF (&amp;gt;7 days continuous AF). 9 (53%) patients had at least 1 episode of self-limited paroxysmal AF. In these patients the average paroxysmal AF burden during the follow-up was 24 hours/year [IQR 9-24 hours/year]. In another 8 (47%) patients the recurrent arrhythmia was atypical left atrial flutter exclusively The incidence of procedure-related complications was 6,9%: 1 pericardial bleeding, 1 acute pulmonary edema, 1 splenic infarction and 1 stroke); no patient died during the study period. Conclusions A combined strategy of PVI plus the specific linear ablation protocol used in this study is associated with a low rate of atrial arrhythmia recurrences and total absence of persistent AF after ablation. A randomized multicenter clinical trial is ongoing to validate these results.Ablation strategy.Kaplan-Meier curve: recurrences

К ВОПРОСУ О НАРУШЕНИИ СЕРДЕЧНОГО РИТМА В КОСМИЧЕСКОМ ПОЛЕТЕ

It is common knowledge that during space missions (SMs) the cosmonauts are subjected to stresses. One of potential SMs problems is disorders in the bioelectrical parameters of the myocardium conductivity or arrhythmias. The paper analyzes the results of investigations into the changes of cardiac rhythm variability in a group of 5 cosmonauts (46 ± 4.5 yrs of age) using ECG records containing episodes of atrial and/or ventricular arrhythmias. Mean mission duration of each cosmonaut was about six months as a standard. Analysis of the experimental data on occurrence of cardiac rhythm disorders may point to SMs arrhythmogenicity. It was shown that frequency of ventricular extrasystoles in SMs increases in comparison with the baseline data. Atrial extrasystoles become more frequent by the end of SMs. The largest numbers of extrasystoles were recorded after extravehicular activities (EVAs). Assembly of the Russian orbital (service) station RO(S)S will increase the number of EVAs which should be taken into account, as additional loading on the cardiovascular system may provoke disorders in the cardiac rhythm.

Snoring and lack of REM sleep is associated with same-day atrial arrhythmias in a cohort of patients with atrial fibrillation: initial results of TriggersAF

Abstract Introduction Sleep-disordered breathing (SDB) is a known risk factor for the development of atrial fibrillation (AF). Few studies analyse the temporal relation between snoring, sleep phases and atrial arrhythmia episodes. Purpose The TriggersAF trial (NCT05526170) investigates the temporal relation between atrial arrhythmias and potential triggers. In this preliminary analysis, the authors hypothesised that snoring and disturbance of sleep phases may be associated with same-day atrial arrhythmias. Methods In a single-centre prospective cohort study patients with previously diagnosed AF were recruited for home monitoring of 7 days. A single-lead continuous electrocardiogram (ECG) of the reference Holter monitor (Bittium, Kuopio, Finland) documented the cardiac rhythm. The recordings were manually annotated as: 1) AF, 2) atrial tachycardia or flutter (AT), 3) frequent premature atrial contractions (PAC), defined as bigeminy, trigeminy, quadrigeminy or couplets, and 4) no arrhythmia. Sleep disorders were evaluated using a validated sleep tracking mat (Withings Sleep Analyzer, Issy-les-Moulineaux, France) and described by the number of snoring episodes, durations of snoring, light, deep, and rapid-eye-movement (REM) phases. Heart echocardiography with strain imaging of left atrium (LA) was performed to further characterize the subjects. Results The study consisted of 49 patients, aged 55.8±11.7 years, 67.3% male. All patients were with previously diagnosed non-permanent AF and sinus rhythm at the moment of inclusion. The monitoring duration yielded a total of 300 days. The occurrence of AF, AT and PAC was detected in 32/300, 108/300 and 85/300 of days, respectively. As revealed by the sleep analysis a greater number of snoring episodes was associated with the same-day episodes of AF when compared to patients with no AF (5.0 (2-10.2) vs. 2.0 (0-7), P=0.029, respectively). A longer snoring duration was associated with the same-day episodes of AF (36 (6-80) min vs. 12 (0-52) min, P=0.057). A shorter duration of the REM phase was associated with AT (63 (28-93) min vs. 79 (42-105) min, P=0.032) and PAC (60 (32-91) min vs. 79 (37-102) min, P= 0.058). No significant relations were observed between the durations of light or deep phases and any type of arrhythmias. A smaller mean conduit strain of LA was highly associated with AF (-7,5 (-12,5, -7,5)) compared to patients with no AF (-11,0 (-14,8, -8,5), P= 0.002). In the Fast-and-Frugal Decision Tree for the prediction of same-day AF, a model combining the mean conduit strain of less than -9, a body mass index of more than 27.8, and a snoring duration of more than 29 minutes yielded a sensitivity of 97%, a specificity of 59% and a balanced accuracy of 78%. Conclusions The higher frequency and duration of snoring, as well as reduced REM phase of sleep are linked to same-day atrial arrhythmias. Long-term SDB monitoring and LA strain imaging predict the episodes of AF with high accuracy.Number of snoring episodes vs. AFAF by LA strain, BMI and snoring

Effects of CRT on atrial and ventricular arrhythmias in patients with HF

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Cardiac resynchronization therapy (CRT) is an accepted treatment for patients with heart failure (HF). Cardiac arrhythmias present a significant and complex issue in this patient group. Evidence exploring the influence of CRT on cardiac arrhythmias rate variations is limited. Purpose Our research investigates the effectiveness of CRT in the treatment of existing and newly diagnosed atrial and ventricular arrhythmias, and impact of epicardial lead position on these arrhythmias rate variations, as well as on the CRT response. Methods This single-center, prospective, observational study included 75 consecutive patients admitted for CRT implantation over a 12-month period. All included patients had episodes of atrial and/or ventricular arrhythmias, diagnosed by 12-lead ECG or 24-hour Holter monitoring. Pre-procedural demographic characteristics were collected for all patients, including ECG records, NYHA functional class, echocardiographic assessment of left ventricular ejection function and questionnaire for quality-of-life. During device follow up atrial and ventricular arrhythmias appearance was monitored. Additional assessment of echocardiographic parameters, NYHA - functional class, quality of life and rate of major cardiovascular complications and rehospitalizations was performed. Results The mean age of the patients was 62.4 ± 10.3 years, with 74.6% male and 25.3% females. 72% had a non-ischemic HF etiology. Pre-procedural paroxysmal AF was present in 34.7%, persistent AF in 36%, PVCs in 32%, NSVT 16%, and VT in 18,7% patients. 55% of the included patients were responders to CRT. Our results showed decrease in rate of all ventricular arrhythmias, with significant reduction in the percentage of VT (p=0.003), regardless of CRT response. Significant reduction of PVCs and NSVT rate (p=0.012 &amp; p=0.024) was found in the responder group of patients. Regarding AF, our results showed a decrease in the number of AF events in both patient groups, however this was most visible in the responder patients with paroxysmal AF (p=0.057). In CRT responders, left ventricular pacing lead was most commonly located in a lateral branch vein of the CS with middle and mid/lateral position. In terms of quality of life and general condition of the patients, we noticed a significant improvement in the NYHA - functional class (p &amp;lt;0.001), as well as in both parts of the quality-of-life assessment questionnaire (p=0.0135, p&amp;lt;0.001). Conclusion CRT is an effective treatment for atrial and ventricular arrhythmias in HF patients, especially in responders to this therapy. LV epicardial lead position proved to be very important influence in the process of LV reverse remodeling, which is in direct correlation of the CRT responders and its effectiveness in reducing the rate of cardiac arrhythmias.

Abstract 14452: Do Patient-Reported Symptoms on Ambulatory Electrocardiogram Correlate With Atrial Arrhythmia Episodes?

Introduction: Guidelines regarding rhythm control for atrial arrhythmias (AT/AF) are primarily based on symptom burden. Ambulatory electrocardiogram (AECG) monitoring is often performed to evaluate AT/AF burden and guide clinical decision-making. Yet, to date, little is known about the correlation of symptoms reported during AECG with recorded AT/AF. Methods: University of Utah patient AECGs with at least one AT/AF event over 7 or more days of monitoring were retrospectively reviewed - only events with symptoms or with AT/AF were included (other arrhythmias were rare and excluded). Patient triggered symptoms included reported shortness of breath, tiredness, palpitations, dizziness, or passing out. Tetrachoric correlation analysis was performed to evaluate the correlation between symptoms and AT/AF episodes. Results: We identified 742 patients with a mean age of 64 years, 50% female, 22% with chronic heart failure, overall mean CHA 2 DS 2 -VASc score of 2.5 and 67% with scores ≥2. There were 6,289 symptomatic events and 6,900 AT/AF episodes. Among these were 1,025 (16%) episodes of shortness of breath, 854 (14%) of tiredness, 2,660 (42%) of palpitations, 794 (13%) of dizziness, and 95 (2%) of passing out. Symptomatic events were less likely to predict simultaneous AT/AF compared to sinus rhythm on AECG, with a moderate inverse tetrachoric correlation of -0.66 (range -1 to 1, with 1 representing perfect positive correlation). Conclusion: Patient-triggered symptomatic events were inversely correlated with recorded AT/AF events and represented an unacceptable marker of actual arrhythmia. A more holistic approach to assessment of ATAF symptoms is needed to improve patient selection for rhythm control therapy.

Contrast defect of left atrial appendage on computed tomography is associated with higher risk of recurrence after catheter ablation in patients with paroxysmal atrial fibrillation.

The previous study has shown that the contrast defect of the left atrial appendage (LAA) on contrast-enhanced cardiac computed tomography (CT) is associated with a higher rate of stroke in patients with atrial fibrillation (AF). This study aimed to investigate the association between LAA CT contrast defect and the risk of arrhythmia recurrence after catheter ablation (CA) in patients with paroxysmal AF. A total of 283 paroxysmal AF patients [age: 67 ± 10years, 185 (65%) males] who underwent cardiac CT before CA were retrospectively analyzed. The presence or absence of LAA CT contrast defect was visually assessed using early phase CT images. Recurrence was an episode of atrial arrhythmia beyond the first 90days post-ablation. LAA flow velocity was measured using transesophageal echocardiography in 246 paroxysmal AF patients. Sixty-eight (24%) patients had an LAA CT contrast defect. LAA flow velocity was significantly reduced in patients with LAA CT defect compared to those without (56.8 ± 28.7cm/s vs. 41.1 ± 19.1cm/s, p < 0.001). During a median follow-up period of 858days, arrhythmia recurrence was identified in 85 (30%) patients. On a Kaplan Meier curve, patients with LAA CT contrast defect had significantly higher recurrence rates than those without (p = 0.043). On a multivariable Cox regression analysis, LAA CT contrast defect was a significant and independent predictor after adjustment of age, sex and left atrial volume index (hazard ratio: 1.79, 95% confidence interval: 1.03-3.07, p = 0.036). LAA CT contrast defect was associated with decreased LAA flow velocity and a higher rate of arrhythmia recurrence after CA, suggesting its usefulness as a non-invasive predictor for high-risk AF patients resistant to CA therapy.

Utilising the pericardial CO2 insufflation technique to facilitate endo-epicardial AF ablation, achieving linear radiofrequency lesion sets, for persistent atrial fibrillation

Abstract Funding Acknowledgements Type of funding sources: None. Background High rates of persistent atrial fibrillation (PsAF) recurrence have been attributed to conduction gaps, non-transmural linear lesion sets and epicardial substrate. Hybrid thorascopic endo-epicardial AF ablation has been shown to reduce PsAF recurrence when compared to endocardial ablation alone, however with higher complication rates. Aim We propose that the percutaneous pericardial CO2 insufflation technique to access the pericardial space can be safely and effectively used for epicardial mapping and ablation of the left atrium (LA). Methods In a single centre, 15 patients with PsAF (6 with longstanding PsAF) and previous pulmonary vein isolation (PVI), underwent concurrent endo-epicardial AF ablation, using the subxiphoid percutaneous pericardial CO2 insufflation technique, whilst on uninterrupted anticoagulation. Endo-epicardial geometry and bipolar voltage maps were undertaken, and endocardial LA ablation performed comprising a roof, inferior and anterior mitral line (AML) (target LSI 5 for the inferior line and 6 on the roof and AML). If required, additional epicardial ablation was undertaken to establish PVI and linear lesion block. Results Epicardial access was achieved in all patients without acute bleeding complication. Epicardial mapping of the LA, in both transverse and oblique pericardial sinuses, was successful in all patients (Figure 1A, B). Excluding one roof line, all other linear lesions were blocked (44/45). Endocardial ablation alone achieved block in 67% (10 of 15) of roof lines, 87% (13 of 15) of inferior lines and 27% (4 of 15) of AMLs despite extensive endocardial ablation. Of AMLs requiring epicardial ablation, in 91% (10/11) block was achieved with ablation on the upper third of AML via the transverse sinus (Figure 1C). Epicardial ablation directly on the roof line via the transverse sinus was required to achieve block in 3 cases, and block achieved remotely on the upper third of the AML in another. Epicardial ablation on the mid inferior line was required in 2 cases to achieve block. Six patients had arrhythmia recurrence during the blanking period with 5 patients requiring DCCV and 1 patient chemically cardioverting. With a mean follow up time of 225 days, 2 patients have had paroxysmal self-terminating episodes of atrial arrhythmia with all patients off anti-arrhythmic medication. Conclusion Use of the subxiphoid percutaneous pericardial CO2 insufflation technique to achieve epicardial access for LA mapping and ablation is feasible and safe whilst on uninterrupted anticoagulation. Limited success in ablation for PsAF beyond PVI may be due to difficulty in creating trans-mural linear lesions. Epicardial ablation can be safely performed to achieve linear block in the roof, anterior and inferior LA. Epicardial fibrous structures such as the septopulmonary bundle and Bachmann’s bundle likely contribute to difficulty blocking roof lines and AMLs endocardially.

Detection of atrial fibrillation in patients with cryptogenic stroke: The Nordic Atrial Fibrillation and Stroke (NOR-FIB) study - topline results

Abstract Funding Acknowledgements Type of funding sources: Other. Main funding source(s): NOR-FIB is an investigator driven academic study. 100 of 259 devices are supported by Medtronic. BRT and ATL are recipients of a PhD grants from the South-Eastern Norway Regional Health Authority. The study is supported by the research infrastructure of the European Cerebrovascular Research Infrastructure (ECRI). Background Cardioembolism due to occult atrial fibrillation (AF) is one of the common causes often identified by additional investigations in patients with cryptogenic stroke (CS). A large proportion of recurrent cerebral infarctions caused by AF can probably be prevented if more patients receive optimal cardiac monitoring after CS and TIA. Purpose The aim of the prospective observational multi-center NOR-FIB study was to detect and quantify AF in patients with cryptogenic stroke or TIA under continuous 12 months cardiac rhythm monitoring with an implantable cardiac monitor (ICM) and to possibly identify biomarkers predicting incident AF. Methods Patients with cryptogenic stroke and TIA diagnosed after state-of-the-art work-up had their ICM implanted by a stroke physician within 14 days after symptom onset. All patients were followed clinically and by rhythm monitoring for 12 months. AF was defined by detected atrial arrhythmia episodes ≥ 2 min, and these patients were considered for a change of their secondary prevention from antiplatelet drugs to oral anticoagulants (OAC). Results A total of 259 patients with cryptogenic stroke or TIA from 18 hospitals in Norway, Sweden and Denmark were included. After 12 months follow-up 74 (28.6 %) patients were diagnosed with paroxysmal AF, of which 91.9% were asymptomatic. Patients with AF had significantly higher mean age (72.6 vs 62.2, p&amp;lt;0.001), more severe stroke (median National Institute Stroke Scale Score on admission 2 vs 1, p 0.002) and higher pre-stroke median CHA2DS2-VASc score (3 vs 2, p&amp;lt;0.001) than patients without AF. Both hypertension and hyperlipidemia was more common in patients with AF. In 64 (86.5%) cases AF was detected early after index stroke, i.e., within the first two months of monitoring (mean 47.7 days + 52,1). Recurrent AF episodes were detected in 68 (91.9%) cases. Of the 74 AF patients, 72 (97.3%) were switched to OAC. Recurrent strokes during follow-up occurred in 2 AF patients (2.7 %) and in 9 non-AF patients (4.9 %). Conclusion AF was detected in 29% of all cryptogenic stroke/TIA patients. Most of the patients were asymptomatic for their arrhythmia, and would have gone undiagnosed without a continuous monitoring approach. Since most of the patients with detected AF were switched to OAC, the 12 months risk of recurrent stroke in this group was low. Prolonged cardiac rhythm monitoring with ICMs is an effective tool for diagnosing underlying asymptomatic AF in a patient population typically confined to a stroke unit.

Lower Incidence of Postoperative Atrial Arrhythmia After Prophylactic Donor Heart Tricuspid Annuloplasty in Orthotopic Heart Transplantation

<h3>Purpose</h3> Donor heart tricuspid valve annuloplasty (dTVA) may reduce incidence of tricuspid regurgitation after orthotopic heart transplantation (OHT) but data on short-term hemodynamics outcome after prophylactic dTVA is limited. We hypothesized that prophylactic dTVA could benefit post-operative hemodynamics by minimizing right atrial pressure and atrial fibrillation. In our program, we have two primary OHT surgeons, one who routinely uses a DeVega dTVA and one who does not, presenting an opportunity for the study. <h3>Methods</h3> We retrospectively evaluated 52 consecutive OHT recipients between January 2020 and September 2021. They were divided into standard bicaval OHT group (sOHT; n = 28) and bicaval OHT with De Vega dTVA group (dvTVA; n = 24). Incidence of atrial fibrillation, hemodynamics, intensive care unit (ICU) length of stay (LOS), total LOS and echocardiographic measurements were reviewed and analyzed. <h3>Results</h3> Of 52 OHT recipients, mean age was 54.4 ± 11.3 years and 13 (25%) were female. There was no difference between groups in ICU or total LOS, days on inotropic support and in-hospital mortality. Hemodynamically, mean central venous pressure (CVP) at one week, four weeks and three months was not significantly different between groups. Proportion of recipients with significant v wave from CVP tracing wave form in the sOHT group trended higher but without statistically significance compared to dvTVA group and lowered overtime (46.1% vs 26.1%, p = 0.23 at one week, 25.0% vs 20.8%, p = 0.75 at four weeks and 16.6% vs 9.5%, p = 0.67 at three months). However, at mean follow-up of 7.4 months, incidence of atrial arrhythmia including atrial fibrillation and atrial flutter in sOHT group was significantly higher than in dvTVA group (32.1% vs 8.3%, p = 0.046) and most of atrial arrhythmia episodes occurred within one month post-operatively. <h3>Conclusion</h3> We show that OHT recipients with dTVA have lower incidence of atrial arrhythmia and trend to have less significant atrial v waves compared with sOHT patients. Interestingly, over time, the v wave in sOHT recipients normalized, suggesting improvement in RV function. Further study is needed to evaluate long-term outcome with prophylactic dTVA in OHT, incidence of amiodarone use and long term survival.

Incidence, Risk Factors, and Outcomes of Atrial Arrhythmias in Adult Patients With Atrioventricular Septal Defect.

This study aimed to assess the incidence, associated factors, and outcomes of atrial arrhythmias in adults with atrioventricular septal defect (AVSD). Data regarding atrial arrhythmias in adults with AVSD are particularly scarce. Data were analyzed from a multicentric cohort of adult patients with AVSD. Lifetime cumulative incidences of atrial arrhythmias were studied. Multiple logistic regression models were used to identify risk factors. A total of 391 patients (61.6% women) were enrolled with a mean age of 36.3 ± 16.3 years and a mean follow-up of 17.3 ± 14.2 years after initial surgical repair. Overall, 98 patients (25.1%) developed at least 1 episode of atrial arrhythmia at a mean age of 39.2 ± 17.2 years. The mean ages of patients at first episode of intra-atrial re-entrant tachycardia (IART)/ focal atrial tachycardia (FAT) and atrial fibrillation were 33.7 ± 15.3 and 44.3 ± 16.5 years, respectively. The lifetime risks for developing atrial arrhythmia to ages 20, 40, and 60 years were 3.7%, 17.8%, and 55.3%, respectively. IART/FAT was the leading arrhythmia until the age of 45, then atrial fibrillation surpassed IART/FAT. Age (odds ratio [OR]: 1.4; 95% confidence interval [CI]: 1.2-1.6), number of cardiac surgeries (OR: 4.1; 95%CI: 2.5-6.9), left atrial dilatation (OR: 3.1; 95%CI: 1.4-6.8), right atrial dilatation (OR: 4.1; 95%CI: 1.7-10.3), and moderate or severe left atrioventricular valve regurgitation (OR: 3.7; 95%CI: 1.2-11.7) were independently associated with a higher risk of atrial arrhythmias, whereas the type of AVSD and the age at repair were not. The occurrence of atrial arrhythmias was associated with pacemaker implantation (41.8% vs. 8.5%; P< 0.001), heart failure (24.5% vs. 1.0%; P< 0.001), and cerebrovascular accidents (11.2% vs. 3.4%; P = 0.007). The lifetime risk of atrial arrhythmias in patients with AVSD is considerable with more than half of patients developing≥1 atrial arrhythmia by the age of 60 and is associated with a significant morbidity. The risk in partial/intermediate AVSD is as high as in complete AVSD and is not impacted by age at repair.

Effectiveness of radiofrequency renal denervation in diseases with increased sympathetic nervous system activity

The article discusses the role of sympathetic nervous system hyperactivity in the pathogenesis of various pathologies (hypertension, heart failure, atrial fibrillation, metabolic syndrome, diabetes and systemic inflammatory response syndrome). On the example of large randomized clinical trials using catheter-based radiofrequency ablation, the antihypertensive effect in patients with uncontrolled hypertension has been proven. The first experimental and clinical studies on the effectiveness of renal denervation in reducing the activity of inflammatory markers, the incidence of atrial fibrillation and ventricular arrhythmia episodes, and improving the left ventricular contractility. The first clinical results of the favorable effect of renal denervation on carbohydrate metabolism (insulin resistance and glycemic level) in patients with metabolic syndrome and diabetes have been studied in detail.

Six-month outcomes of a high intensity exercise programme in young patients with hypertrophic cardiomyopathy: The SAFE-HCM trial

Abstract Funding Acknowledgements Type of funding sources: Other. Main funding source(s): Cardiac Risk in the Young Background Moderate intensity exercise training in older patients with hypertrophic cardiomyopathy (HCM) can improve functional capacity, without significant harm. However, younger patients are attracted to high intensity training (HIT) regimes. The SAFE-HCM study demonstrated that an individually tailored, HIT programme in young patients with HCM was feasible, and provided both health and psychological benefits, without an increase in the burden of arrhythmia. Purpose To assess whether observed benefits of a HIT programme in young patients with HCM are sustained at 6 months. Methods Eighty patients with HCM (45.7y+/-8.6) underwent baseline clinical and psychological assessment. Individuals were randomised to a 12-week HIT programme (n = 40) or usual care (n = 40). Baseline evaluation was repeated at 12 weeks (T12). Feasibility, safety, health and psychological benefits were assessed. At 12-weeks individuals were encouraged to continue with the frequency and intensity of physical activity (PA) achieved at the end of the cardiac rehabilitation programme. Participants in the exercise arm were invited to follow-up at 6 months (T6m). Results The majority (83%) of participants completed the 12-week study. At T12 there was no significant difference between groups in the composite arrhythmia safety outcome (p = 0.99). The indices of exercise capacity were significantly improved in the exercise compared to the control group; peak VO2 (+3.7ml/kg/min [CI 1.1,6.3], p = 0.006), VO2/kg at anaerobic threshold (VO2/kgAT) (+2.44ml/kg/min [CI 0.6,4.2], p = 0.009), time to AT (+115s [CI 54.3,175.9], p &amp;lt; 0.001) and exercise time (max ET) (+108s [CI 33.7,182.2], p = 0.005). The exercise group also demonstrated greater reduction in systolic BP (-7.3mmHg [CI -11.7,-2.8], p = 0.002), BMI (-0.8kg/m2 [CI-1.1,-0.4], p &amp;lt; 0.001), anxiety (-2.6 [CI-3.6,-1.6], p= &amp;lt;0.001) and depression (-1.1 [CI -2.0,-0.2], p = 0.015) scores. At T6m patient reported exercise adherence was comparable to baseline PA in 33/34 of the exercise group attending for follow up. Most exercise gains dissipated with the exception of time to AT (p = 0.002), max ET (p = 0.003), VO2/kgAT (p = 0.04) and anxiety score (p &amp;lt; 0.001) (Figure 1). There were no sustained episodes of atrial or ventricular arrhythmias. The incidence of NSVT did not differ between time points (p = 0.09). Conclusion A 12-week HIT programme in young patients with HCM offers considerable gains in fitness and psychological outcomes, with no increase in arrhythmic burden. At T6m exercise levels as well as most physiological adaptations and health benefits returned to baseline, as seen in other studies when formal participation in an exercise programme comes to an end. This highlights the importance of the implementation of strategies to encourage ongoing engagement in PA. Potential solutions include identification of barriers to exercise, as well as adoption of novel tele-rehabilation approaches. Abstract Figure 1 Sustained benefits at T6m

Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation.

AimsTreatment guidelines for patients with atrial fibrillation (AF) suggest that patients should be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA). This study evaluated whether pulmonary vein isolation employing cryoballoon CA is superior to AAD therapy for the prevention of atrial arrhythmia (AA) recurrence in rhythm control naive patients with paroxysmal AF (PAF).Methods and resultsA total of 218 treatment naive patients with symptomatic PAF were randomized (1 : 1) to cryoballoon CA (Arctic Front Advance, Medtronic) or AAD (Class I or III) and followed for 12 months. The primary endpoint was ≥1 episode of recurrent AA (AF, atrial flutter, or atrial tachycardia) >30 s after a prespecified 90-day blanking period. Secondary endpoints included the rate of serious adverse events (SAEs) and recurrence of symptomatic palpitations (evaluated via patient diaries). Freedom from AA was achieved in 82.2% of subjects in the cryoballoon arm and 67.6% of subjects in the AAD arm (HR = 0.48, P = 0.01). There were no group differences in the time-to-first (HR = 0.76, P = 0.28) or overall incidence [incidence rate ratio (IRR)=0.79, P = 0.28] of SAEs. The incidence rate of symptomatic palpitations was lower in the cryoballoon (7.61 days/year) compared with the AAD arm (18.96 days/year; IRR = 0.40, P < 0.001).ConclusionsCryoballoon CA was superior to AAD therapy, significantly reducing AA recurrence in treatment naive patients with PAF. Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.

Recurrent sustained atrial arrhythmias and thromboembolism in Fontan patients with total cavopulmonary connection.

BackgroundTotal cavopulmonary connection (TCPC) is associated with a lower risk of incident atrial arrhythmias as compared to atriopulmonary Fontan, but the risk of recurrent atrial arrhythmias is unknown in this population. The purpose of this study was to determine the incidence and risk factors for recurrent atrial arrhythmias and thromboembolic complications in patients with TCPC.MethodsThis is a retrospective multicenter study conducted by the Alliance for Adult Research in Congenital Cardiology (AARCC), 2000–2018. The inclusion criteria were TCPC patients (age > 15 years) with prior history of atrial arrhythmia.ResultsA total of 103 patients (age 26 ± 7 years; male 58 [56%]) met inclusion criteria. The mean age at initial arrhythmia diagnosis was 13 ± 5 years, and atrial arrhythmias were classified as atrial flutter/tachycardia in 85 (83%) and atrial fibrillation in 18 (17%). The median duration of follow-up from the first episode of atrial arrhythmia was 14.9 (12.1–17.3) years, and during this period 64 (62%) patients had recurrent atrial arrhythmias (atrial flutter/tachycardia 51 [80%] and atrial fibrillation 13 [20%]) with annual incidence of 4.4%. Older age was a risk factor for arrhythmia recurrence while the use of a class III anti-arrhythmic drug was associated with a lower risk of recurrent arrhythmias. The incidence of thromboembolic complication was 0.6% per year, and the cumulative incidence was 4% and 7% at 5 and 10 years respectively from the time of first atrial arrhythmia diagnosis. There were no identifiable risk factors for thromboembolic complications in this cohort.ConclusionsAlthough TCPC provides superior flow dynamics and lower risk of incident atrial arrhythmias, there is a significant risk of recurrent arrhythmias among TCPC patients with a prior history of atrial arrhythmias. These patients may require more intensive arrhythmia surveillance as compared to other TCPC patients.

Abstract 15102: Benign Cardiac Neoplasms in the United States - A Thirteen-year Review

Introduction: Benign cardiac neoplasms (BCN) are rare; with varying reported incidence and a paucity of epidemiologic studies. The purpose of our review was to add to the small body of literature describing the characteristics and trends of BCN in the US. Methods: This study is a retrospective review of data from the HCUP-NIS Database from 2002-2014. Inclusion criteria consisted of the presence of indication for BCN. Additionally, we queried the database for BCN-associated comorbidities. SAS studio was utilized for analysis. Results: The data consisted of 482,872,274 weighted discharges. There were 45,568 weighted discharges that had BCN. Sixty four percent were women. Median cost per admission was 51,799 USD, five times higher than the national average. A total of 1,267 (2.78%) patients died during the admission. Stroke and arterial embolization were reported in 6730 (14.76%) and 573 (1.26%) weighted discharges. Weight loss, fever and endocarditis were reported in 311 (0.68%), 383 (0.84%) and 869 (1.91%) patients, respectively. Pulmonary hypertension co-occurred in 3440 (7.55%) patients. Episodes of atrial tachyarrhythmias, ventricular arrhythmias, syncope and cardiac arrest were reported in 13,184 (28.93%), 1,471 (3.23%), 1,055 (2.32%) and 393 (0.86%) cases. Sinus node dysfunction, severe AV nodal block co-occurred in 1,005 (2.21%) and 930 (2.04%) patients. Conclusions: We identified a low incidence of BCN in the US over the 13-year study period. Since the prevalence for BCN is low, clinicians must maintain a high index of suspicion due to the high morbidity and mortality.

Patients with Fontan circulation beyond the fourth decade of life

Abstract Background The survival rate after Fontan procedure is improving and many of these patients now survive well into adulthood. Data on the late morbidity and mortality of Fontan patients in their fourth decade of life are lacking. Purpose To evaluate the late outcome of adult patients with Fontan circulation who have survived beyond 35 years. Methods Data were collected retrospectively on consecutive patients with a Fontan circulation ≥35 years between 2005 and 2019. Baseline (at 35th birthday) and follow-up data includes functional class, blood tests, history of arrhythmia, heart failure (HF), thromboembolism, Fontan related liver disease (FLD), protein losing enteropathy (PLE) and plastic bronchitis. Echocardiographic data on systemic atrioventricular valve (SAVV) regurgitation and ventricular function were also analysed. Results 61 patients were included (29, 47.5% female). Tricuspid atresia was the most common underline anatomy (29,47.5%) and the median age at Fontan procedure was 12 [8.0–19.0] years. 34 (56%) patients had an atrio-pulmonary connection Fontan and 15 (24.5%) total cavo-pulmonary connection (86.7% lateral tunnel and 13.3% extra-cardiac conduit), 10 (16%) a Bjork Fontan and 2 (3%) a Kawashima procedure. At baseline 40 (66%) patients were in NYHA class II or III, 7 (11%) had a moderate or severely impaired ventricular function and 12 (20%) had at least moderate SSAV regurgitation. At baseline, 35 (57.4%) patients had experienced at least one arrhythmia, 7 (11.4%) patients had a history of atrial thrombosis or thromboembolic events and 2 (3.3%) of PLE. At a median follow-up of 6.4 [2.9–11.3] years, 11 (18%) patients died, 7 of chronic HF, 1 hepatic carcinoma, 1 sepsis, 1 pulmonary embolism, 1 malignancy (1 cause unknown). During follow-up, 28 (46%) patients had a new episode of atrial arrhythmia, 23 (38%) developed FLD and 2 (3.3%) PLE. 9 (15%) required at least one admission for HF. 2 (3.3%) patients experienced worsening of their ventricular function and 7 (11.4%) of their SAVV regurgitation. On univariable analysis, a baseline diagnosis of PLE (HR 15.23, 95% CI:2.77–83.86, p=0.002), HF (HR 6.18, 95% CI:1.74–21.99, p=0.005), atrial arrhythmia (HR 4.99, 95% CI:1.07–23.21, p=0.04), lower serum albumin (HR 1.14, 95% CI:1.06–1.23, p=0.0006), lower iron levels (HR 1.31, 95% CI:1.02–1.68, p=0.04) and a higher urea (HR 1.18, 95% CI:1.04–1.34, p=0.01) were associated with death or heart transplantation. On bivariable analysis, lower serum albumin was stronger than all other univariable predictors. Conclusions Adult Fontan survivors are a high risk population with significant morbidity and mortality driven primarily by HF and other long-term complications of the Fontan operation. The predictors of outcome in this cohort reflects the chronic low cardiac output state and systemic venous hypertension. Vigilance is required to identify patients who may benefit of haemodynamic optimization and close monitoring for Fontan-related complications. Funding Acknowledgement Type of funding source: None